Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Comment by MementoMorion Jul 18, 2008 10:57am
327 Views
Post# 15306240

RE: Similiar stage, totally different stock price?

RE: Similiar stage, totally different stock price?> Cardiome Corp, a very similar stage biotech company to ISA, its SP rocket rockets at Positive Phase II results! And its price is now over 11 dollars, 16 times higher than ISA's.

I don't know anything at all about Cardiome. You are certainly right that is valued much more highly than ISA, but I feel compelled to point out (not for the first time) that comparing share prices head to head is a completely meaningless exercise. Cardiome has 63.7 million shares; ISA has 106.2 million. If you want to compare valuations, compare their markets caps: $69 million for ISA versus $715 million for Cardiome. So Cardiome is valued about 10.4 times more than ISA. If Cardiome sits at $11 (and doesn't issue any new shares), ISA has to make it to  $6.73 to be valued equally.
Bullboard Posts